Atropos Health Expands Oncology Network with Ontada Partnership PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a company known for converting clinical real-world data (RWD) into personalized real-world evidence (RWE) and insights, has forged a strategic alliance with Ontada®, a McKesson business that specializes in community oncology RWD, clinical education, and point-of-care technologies. This partnership aims to enhance the capabilities of clinicians, researchers, and healthcare leaders in designing care protocols, advancing precision medicine, and developing new oncology treatments. Atropos Health’s automation tools, powered by the GENEVA OS™ platform, integrate seamlessly into customers' internal cloud data environments, enabling them to generate evidence from their own data. The Atropos Evidence™ Network stands as the largest federated data network in healthcare, encompassing over 300 million patient records. Network members can run queries on this vast RWD repository, ensuring they access the most relevant data for their specific questions, as validated by the Real-World Fitness Score®. “The demand for high-quality oncology data is relentless,” Dr. Brigham Hyde, CEO and co-founder of Atropos Health, stated. “By incorporating Ontada’s RWD into the Atropos Evidence™ Network, we will offer health systems the critical data needed to make informed, high-stakes clinical decisions. For life sciences organizations, this collaboration will expedite the use of RWE insights in drug discovery and development, fostering innovation and ultimately enhancing the lives of cancer patients.” Ontada's insights are particularly valuable in the community oncology setting, where roughly 85% of cancer patients receive treatment. Ontada sources its proprietary database, iKnowMed®, from The US Oncology Network, which treats more than 1.4 million cancer patients annually. iKnowMed® provides comprehensive data on the patient journey, covering over 2.4 million patients across more than 80 tumor types. This unique dataset offers a detailed view of community cancer care, making it an invaluable resource for understanding and improving patient outcomes. “Both Ontada and Atropos Health share a commitment to accelerating evidence generation and improving cancer patient outcomes,” Christine Davis, President of Ontada, emphasized. “This collaboration will bolster the evidence-generation capabilities of life sciences organizations and support more effective clinical decision-making, leading to better patient care.” The partnership also builds on Atropos Health’s recent introduction of Federated Nodal Deidentification Technology, which will be integrated into the GENEVA OS™ platform and made available to all Atropos Evidence™ Network members. This technology ensures that longitudinal patient records maintain a complete view of the patient journey, providing deeper and more actionable insights. About Atropos Health Atropos Health is the pioneering developer of GENEVA OS™, an operating system designed to rapidly generate healthcare evidence from a robust network of real-world data. Healthcare and life science organizations collaborate with Atropos Health to bridge evidence gaps from bench to bedside, thereby improving individual patient outcomes through data-driven care and accelerating medical research. The company’s mission is to transform healthcare by delivering timely, relevant real-world evidence. For more information about Atropos Health, visit www.atroposhealth.com or connect with them on LinkedIn and X (Twitter) @AtroposHealth.